ClinicalTrials.Veeva

Menu
F

Florida Retina Institute | North Florida - Jacksonville Southside

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aflibercept
BI 764524
KUS121
OCS-01
AR-14034
RO7446603
ONL1204
BI 771716
dexamethasone

Parent organization

This site is a part of Florida Retina Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 10 total trials

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle...

Active, not recruiting
Diabetic Macular Edema
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Drug: Vehicle

Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based th...

Active, not recruiting
Central Retinal Artery Occlusion
Drug: KUS121 high dose
Drug: Sham procedure

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME)....

Enrolling
Diabetic Macular Edema
Drug: Faricimab
Drug: Aflibercept
Locations recently updated

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling
Diabetic Retinopathy
Drug: BI 764524
Drug: Aflibercept (Eylea®) - US only
Locations recently updated

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: AR-14034 SR implant lower dose
Drug: Sham procedure

Trial sponsors

Boehringer Ingelheim logo
Alcon logo
Bayer logo
Genentech logo
K
Novartis logo
O
O
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems